Tetrous announced successful closure of its Series A financing round, raising a total of $6,500,000. The round was expanded twice from the initial $5,000,000 target due to support from existing investors, strategic partners and new investors.
Funds will be used to increase the company’s market penetration, develop further clinical data showing the improvement in outcomes for patients and expand surgical applications of the company’s patented technology, including for hip, knee, ankle and elbow procedures with existing and new product offerings.
Tetrous has developed the EnFix family of allograft products, designed to enhance healing at the enthesis. The implants are 100% demineralized bone fiber, providing osteoinductivity and osteoconductivity.
“We are thrilled with the success of this financing round and the confidence our existing shareholders and strategic partners have placed in us,” said Bradley Patt, PhD., CEO of Tetrous. “This funding is enabling us to further enhance our product offerings, broaden our reach, and continue to deliver exceptional value to our customers. It’s All About the Enthesis.”
Tetrous announced successful closure of its Series A financing round, raising a total of $6,500,000. The round was expanded twice from the initial $5,000,000 target due to support from existing investors, strategic partners and new investors.
Funds will be used to increase the company's market penetration, develop further clinical data showing...
Tetrous announced successful closure of its Series A financing round, raising a total of $6,500,000. The round was expanded twice from the initial $5,000,000 target due to support from existing investors, strategic partners and new investors.
Funds will be used to increase the company’s market penetration, develop further clinical data showing the improvement in outcomes for patients and expand surgical applications of the company’s patented technology, including for hip, knee, ankle and elbow procedures with existing and new product offerings.
Tetrous has developed the EnFix family of allograft products, designed to enhance healing at the enthesis. The implants are 100% demineralized bone fiber, providing osteoinductivity and osteoconductivity.
“We are thrilled with the success of this financing round and the confidence our existing shareholders and strategic partners have placed in us,” said Bradley Patt, PhD., CEO of Tetrous. “This funding is enabling us to further enhance our product offerings, broaden our reach, and continue to deliver exceptional value to our customers. It’s All About the Enthesis.”
Copy to clipboard 
